Literature DB >> 21108454

Affinity-based drug delivery.

Nick X Wang1, Horst A von Recum.   

Abstract

Affinity-based drug delivery systems utilize interactions between the therapeutic drug and the delivery system to manipulate drug loading and to control drug release. In this paper, affinity-based drug delivery system syntheses, types of therapeutic factors delivered, and delivery system loading and release are discussed in detail. The paper is divided into three subsections, based on the type of delivery system: molecular imprinting systems, growth-factor delivery, and cyclodextrin-based delivery. The objective of this paper is to examine the current state of research, highlight the breakthroughs and challenges, point out potential impacts of this relatively new technology, and explore future developmental areas.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21108454     DOI: 10.1002/mabi.201000206

Source DB:  PubMed          Journal:  Macromol Biosci        ISSN: 1616-5187            Impact factor:   4.979


  35 in total

Review 1.  Progress in material design for biomedical applications.

Authors:  Mark W Tibbitt; Christopher B Rodell; Jason A Burdick; Kristi S Anseth
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-24       Impact factor: 11.205

Review 2.  Macroscale delivery systems for molecular and cellular payloads.

Authors:  Cathal J Kearney; David J Mooney
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

3.  Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds.

Authors:  Kara L Spiller; Sina Nassiri; Claire E Witherel; Rachel R Anfang; Johnathan Ng; Kenneth R Nakazawa; Tony Yu; Gordana Vunjak-Novakovic
Journal:  Biomaterials       Date:  2014-10-23       Impact factor: 12.479

4.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Authors:  Christopher B Rodell; Sean P Arlauckas; Michael F Cuccarese; Christopher S Garris; Ran Li; Maaz S Ahmed; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Nat Biomed Eng       Date:  2018-05-21       Impact factor: 25.671

5.  Local delivery polymer provides sustained antifungal activity of amphotericin B with reduced cytotoxicity.

Authors:  Rebecca M Haley; Sean T Zuckerman; Catherine A Gormley; Julius N Korley; Horst A von Recum
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-21

Review 6.  Peptide and protein-based inhibitors of HIV-1 co-receptors.

Authors:  Horst A von Recum; Jonathan K Pokorski
Journal:  Exp Biol Med (Maywood)       Date:  2013-05

7.  Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.

Authors:  Nick X Wang; Scott F Sieg; Michael M Lederman; Robin E Offord; Oliver Hartley; Horst A von Recum
Journal:  Mol Pharm       Date:  2013-08-26       Impact factor: 4.939

8.  A naonoporous cell-therapy device with controllable biodegradation for long-term drug release.

Authors:  Hongyan He; Eric Luedke; Xulang Zhang; Bo Yu; Alessandra Schmitt; Ben McClarren; Valerie Grignol; William E Carson; L James Lee
Journal:  J Control Release       Date:  2012-12-07       Impact factor: 9.776

Review 9.  Controlled drug release for tissue engineering.

Authors:  Kunal J Rambhia; Peter X Ma
Journal:  J Control Release       Date:  2015-08-29       Impact factor: 9.776

10.  Adjustable release of mitomycin C for inhibition of scar tissue formation after filtration surgery.

Authors:  Sonia R Merritt; Gia Velasquez; Horst A von Recum
Journal:  Exp Eye Res       Date:  2013-07-31       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.